Browse drugs

…s with CHD treated with bulevirtide were included in the study. Bulevirtide plasma levels, together with biochemical and virological marker…

… time of data collection, 35 patients had completed 48 weeks of bulevirtide treatment. Among them, 80% (28/35) had VR, 11% (4/35) PVR, 60% …

…esults have been demonstrated in patients with HDV treated with Bulevirtide, a novel HDV entry inhibitor, with improvements in combined vir…

…nkage to specialist care, including access to licensed therapy, bulevirtide (BLV), and recruitment into clinical trials of novel therapies …

…is the most severe form of viral hepatitis. The entry inhibitor bulevirtide (BLV) was recently approved for treatment, but validated predic…

…Immunosuppression 100 (27%)• Azathioprine (38)• Budesonide (7)• Mercaptopurine (5)• Mycophenolate (40)• Prednisolone (4)• Tacrolimus (6) Prima…

…r 10 mg/day for 144W or to 48W of delayed treatment followed by BLV 10 mg/day for 96W (DT-to-10 mg) and 96W posttreatment FU. Effic…

…10 mg monotherapy (n=50), (B) BLV 10 mg for 96W (n=100), or (C) BLV 10 mg for 144W (n=50). Patient follow-up (FU) continued for 48W…

…ients with CHD with and without cirrhosis who were treated with BLV 2 mg for up to 144W reported improvements in their perceived he…

…subset of patients with chronic hepatitis delta (CHD) receiving bulevirtide (BLV) monotherapy achieved undetectable hepatitis delta virus (…